December 16, 2020

Dear Healthcare Provider,

We are writing to provide the latest update regarding the potential for a near-term supply interruption of NATPARA® (parathyroid hormone) for Injection that may impact U.S. patients receiving NATPARA 100-mcg through the Special Use Program (SUP). Since our last communication during the week of November 16, we are notifying you that we are now preparing for a potential near-term supply interruption of NATPARA 75-mcg, in addition to the anticipated supply interruption of NATPARA 100-mcg.

It is important to note that the manufacturing disruptions that are impacting NATPARA supply are fluid. We are working with urgency, and with U.S. regulatory oversight, to address these issues and maintain supply continuity for all NATPARA doses. We could have additional information available as soon as the week of December 21, 2020. In the meantime, we want to ensure that you and your patients receiving NATPARA 100-mcg or NATPARA 75-mcg through the Special Use Program are prepared in the event of near-term supply interruptions for these NATPARA doses.

Please see the following time-sensitive information should you wish to consider alternative treatment plans for patients receiving the 100-mcg dose or the 75-mcg dose of NATPARA. Supply status updates for all other NATPARA doses are also included in this communication.

Time-Sensitive Information Regarding Patients Receiving NATPARA 100-mcg or NATPARA 75-mcg

As we communicated in November, we have been monitoring supply of NATPARA to prepare for potential supply interruptions. We are working with urgency and with U.S. regulatory oversight to resolve the manufacturing issues that are impacting supply. Based on our current assessments, we are anticipating supply interruptions for NATPARA 100-mcg as early as **January 2, 2021**, as well as for NATPARA 75-mcg, as early as **mid-January.**

Takeda cannot make dosing recommendations beyond those reflected in the NATPARA Full Prescribing Information. However, if in your best independent clinical judgement, you would like to change the current NATPARA dose of patients currently receiving the 100-mcg or the 75-mcg dose of NATPARA, please complete and return the enclosed prescription form to expedite the process of updating your patient's NATPARA dose and avoid a disruption in treatment in the event of a supply interruption.

If you have already submitted a prescription form that modifies the dose for a patient currently receiving NATPARA 100-mcg through the SUP, **and the modified dose does not include the use of NATPARA 75-mcg**, there's nothing more that you need to do. In preparation for the anticipated January 2, 2021 supply interruption of the NATPARA 100-mcg dose, the updated prescription form that you've submitted will be processed in advance of the patient's supply interruption. **However, if you have provided a modified dose for a patient currently receiving NATPARA 100-mcg that includes the use of NATPARA 75-mcg, you will need to submit an updated prescription form that does not include the 75-mcg or 100-mcg dosage strengths in order to avoid a disruption to your patient's therapy in the event of a supply interruption.** A Takeda OnePath® Patient Support Manager will follow up with your patient and can answer questions related to supply and the Special Use Program.

For patients currently receiving NATPARA 75-mcg, **or if a modified prescription had been submitted and included NATPARA 75-mcg for a patient currently receiving NATPARA 100-mcg**, please complete and submit the enclosed form. Any changes that you make using the enclosed form will only be processed if a supply disruption occurs. If you need to make an immediate prescription change, please contact OnePath® at 866-888-0660, Monday through Friday 8:30 AM – 8:00 PM ET, to be connected to the pharmacy dispensing the medication for this program.

****Please note that if we do not receive an updated prescription form for any patient currently receiving NATPARA 100-mcg or NATPARA 75-mcg, we will be unable to ship NATPARA to that patient should a supply interruption occur, as anticipated. For patients receiving NATPARA 100-mcg, we would need to receive an updated prescription form by December 22, 2020. For patients receiving NATPARA 75-mcg, we would need to receive an updated prescription form by January 8, 2021.**

For any of your patients who may be affected by a NATPARA dose interruption, please review Section 2.6 (NATPARA Dose Interruption or Discontinuation) and Section 5.4 (Warnings and Precautions: Hypocalcemia) in the enclosed NATPARA Full Prescribing Information. It is very important to closely monitor serum calcium levels and observe for signs and symptoms of hypocalcemia in these patients while carefully adjusting active vitamin D and

supplemental calcium doses. Some patients may require higher doses of active vitamin D and supplemental calcium than doses required prior to starting NATPARA. Additional guidance regarding NATPARA treatment interruption was previously issued in a joint statement by the Endocrine Society and the American Society for Bone and Mineral Research (ASBMR) at the following URL: https://endocrinenews.endocrine.org/endocrine-society-asbmr-issue-joint-statement-on-natpara-recall/.

Update Regarding NATPARA 25-mcg and 50-mcg:
At this time, we do **not** expect SUP-enrolled patients who are receiving **NATPARA 25-mcg** or **NATPARA 50-mcg** to be impacted by near-term supply interruptions. However, we are closely monitoring all NATPARA doses based on the supply demands of the Special Use Program. We are committed to supply continuity and will provide another update on all NATPARA doses by mid-January. We have communicated this information to patients who are receiving NATPARA through the Special Use Program, and we have emphasized to patients receiving NATPARA 25-mcg or NATPARA 50-mcg that there is nothing they need to do at this time.

Compliance with Special Use Program Terms & Conditions
It is important to remind SUP-enrolled patients that each NATPARA cartridge under the Special Use Program (single dose use) is intended for one use only, and that used cartridges with remaining product are to be returned to Takeda in accordance with the Special Use Program (single dose use) instructions. Non-compliance with the rules under the Special Use Program (single dose use) could result in termination of the patient's ability to receive NATPARA product through the program.

Reporting Adverse Events
Heath care providers and patients are encouraged to report adverse events in patients taking NATPARA to Takeda at 1-800-828-2088. You are encouraged to report negative side effects of prescription drugs to the U.S. Food & Drug Administration (FDA). Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Medical Information
You may also contact our medical information department at 1-800-828-2088 if you have any questions about the information contained in this letter or the safe and effective use of NATPARA.

This communication is not intended as a complete description of the benefits and risks related to the use of NATPARA. Please see enclosed the Full Prescribing Information and Medication Guide. For additional information, please call Takeda at 1-800-828-2088 or visit www.natpara.com.

As we have communicated previously, this is a fluid situation and we continue to work with urgency, and with US regulatory authority oversight, to maintain supply continuity for patients receiving NATPARA through the Special Use Program. We could have updated information regarding NATPARA 100-mcg and NATPARA 75-mcg as soon as the week of December 21, 2020. We appreciate your patience as we work to address these issues.

Sincerely,

Tom Koutsavlis
Head, US Medical

Enclosures: NATPARA Full Prescribing Information
Special Use Program Updated Prescription Form

US-NAT-0350v1.0 12/20